Investor Profile: Soleus Capital — Thesis, Cheque Size & How to Apply

Soleus Capital funding suits healthcare founders building in biotech, medtech, diagnostics or genomics, from developmental-stage companies through to commercial-stage businesses. Based in Greenwich, Connecticut, Soleus Capital is a healthcare investment firm that invests across the healthcare lifecycle, and it pairs public-market discipline with private company investing.

Thesis & focus

Soleus Capital focuses on the innovative areas of life sciences. Its edge is lifecycle coverage: it can back a company while its products are still in development and stay with it as it reaches clinicians and patients. That matters for founders whose biggest risk is not the science alone but the long road through regulation, reimbursement and commercial adoption.

Sectors & stages

The firm invests across biotechnology, medical technology, life science tools and diagnostics, and genomics. It works across three strategies: public equity, private equity and structured credit. In practice that means it can invest in a private company, support it through growth, and also participate in public-market financings, giving founders a partner whose view of value is shaped by both sides of the market.

Fund size & cheque size

Soleus Capital does not publish a standard cheque-size range, so cheque size is not publicly disclosed. Company releases put assets under management at around $2 billion. As an illustration of deal scale, Soleus Capital provided a $10 million capital infusion to Longeviti Neuro Solutions in 2025. That single example should not be read as a minimum or maximum cheque.

Notable portfolio

Longeviti Neuro Solutions, a Baltimore-based innovator in functional neurotechnology for complex brain surgery, is a recent private investment, with its implants approved for use in over 120 hospitals. The firm has also been named as a lead investor in healthcare companies including Galecto, Antios Therapeutics and Beta Bionics. Founders should note the distinction: Soleus Capital also holds listed healthcare stocks, but its private-company record is the relevant guide for a startup approach.

Partners & team

Soleus Capital was founded in 2018 by Guy Levy, its founder and Managing Partner, who previously worked at Paulson & Co., Shumway Capital, Warburg Pincus and Morgan Stanley. Ben Lund is a Partner at the firm and led commentary on the Longeviti investment, noting that the firm was introduced to the company by a key opinion leader who had used its products in clinical practice. That detail is telling: clinical credibility and real-world use carry weight with this investor.

Programmes, credits & perks

No public accelerator programme, credits scheme or perks programme was found for Soleus Capital. Its value-add is capital plus healthcare investing experience across public and private markets, and introductions through its clinical and industry network. Founders seeking structured programmes or startup credits should look elsewhere.

How to apply for funding

Soleus Capital does not publish an open pitch-submission form that could be verified. The firm's official site lists its Greenwich office at 100 Field Point Road, Suite 200, Greenwich, CT 06830, and a contact number, and the realistic route for most founders is a warm introduction, ideally from a clinician, operator or investor who knows the team. An approach should lead with clinical evidence, regulatory status and commercial traction, since those were the factors emphasised in its Longeviti investment.